Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 25, 2019 (8 years ago)

Telmisartan and Hyrdochlorothiazide Tablets 40mg/12.5 mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Content Uniformity Specifications: The product is out of specification for blend uniformity.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Telmisartan and Hyrdochlorothiazide Tablets 40mg/12.5 mg, 30-count bottles, Rx Only, Manufactured for:Macleods Pharma USA, Inc. Plainsboro, NJ 08536, Manufactured for: Macleods Pharmaceuticals Ltd. Baddi, Himchal Pradesh INDIA, NDC 33342-128-07

Affected NDC 33342-0128-07

Compare with the code on your package — it is the most precise check available.

Drug: Telmisartan Category: Blood Pressure Medication

Recalling firm
Macleods Pharma Usa Inc
NDC code
33342-128-07
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1003-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Telmisartan recalls

See all
Class II · Moderate risk

Telmisartan Tablets

Failed Stability Specifications: Out of specification for blend uniformity.

Terminated Stability / shelf life Micro Labs Limited NDC 42571-227-30 D-0388-2024
Class II · Moderate risk

Telmisartan and Hydrochlorothiazide Tablets USP

Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-841-13 D-1306-2022
Class II · Moderate risk

Telmisartan and Hydrochlorothiazide Tablets USP

Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-842-13 D-1305-2022

Other recalls by Macleods Pharma Usa Inc

All 2019 recalls
Class III · Low risk

Levofloxacin Tablets

Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Terminated Labeling / mix-up Macleods Pharma USA, INC NDC 33342-022-08 D-0162-2023
Class II · Moderate risk

Eszopiclone Tablets

Shortfill: customer complaints of one to three tablets were reported missing from 30 count bottles.

Terminated Failed specification Macleods Pharma Usa Inc NDC 33342-299-07 D-1174-2022